Conference Presentations

Replicor personnel and collaborators attend and often present at all the major international scientific conferences where HBV or HDV is discussed. Selected presentations can be downloaded below.

Date Conference Location Topic  Abstract/Poster
18.02.2017 APASL 2017 Shanghai, China Update on Safety and Efficacy in the REP 401 protocol APASL 2017 oral presentation
15.11.2016 AASLD 2016 Boston, U.S.A. Preliminary efficacy and safety from the REP 401 trial: REP 2139 / REP 2165 + peg-IFN + TDF in HBeAg negative HBV infection AASLD 2016 oral presentation
14.11.2016 AASLD 2016 Boston, U.S.A. Follow-up results from the REP 301 trial: REP 2139 + peg-IFN in HBV / HDV co-infection AASLD 2016 REP 301 poster
22.9.2016  HBV 2016 Seoul, Korea Effects of nucleic acid polymers on hepatitis B virus entry in HepaRG cells and primary human hepatocytes HBV 2016 HBV Poster
22.9.2016 HBV 2016 Seoul, Korea Inhibition of Hepatitis Delta Virus infection by Nucleic Acid Polymers – an in vitro analysis – HDV 2016 HDV Poster
4.15.2016 EASL 2016 Barcelona, Spain Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection Poster FRI-105 EASL 2016
4.14.2016 EASL 2016 Barcelona, Spain Nucleic acid-based polymers effective against hepatitis B virus infection in patients do not harbour immune stimulatory properties in primary isolated blood or liver cells Poster THU-204 EASL 2016
4.14.2016 EASL 2016 Barcelona, Spain Achievement of surface antigen clearance in the liver by combination therapy with REP 2139-Ca and nucleoside analogues against chronic hepatitis B Poster THU-177 EASL 2016
2.22.2016 APASL 2016 Tokyo, Japan On-treatment reduction of HBsAg and HDV RNA with REP 2139-Ca and pegylated interferon alpha 2a in Caucasian Patients with chronic HBV / HDV co-infection  Replicor REP 301 APASL 2016 O-130web
2.22.2016 APASL 2016 Tokyo, Japan Potentiation of antiviral effect in vivo against HBV by combined therapy with REP 2139-Ca and nucleos(t)ide analogues  Replicor APASL 2016 Combo NAPS In vivo P-0329
8.12.2015 HEP DART 2015 Wailea, Hawaii On-Treatment Reduction of HBsAg and HDV RNA with REP 2139-Ca and Pegylated Interferon alpha 2a in Caucasian Patients with Chronic HBV/HDV  REP301 HEPDART 2015 FINAL (Abstract 60)
8.12.2015 HEP DART 2015 Wailea, Hawaii

Combination Therapy with the Nucleic Acid Polymer REP 2139-Ca and Nucleos(t)ide Analogues Improves Antiviral Responses Against Hepatitis B

In Vivo

 COMBO NAPS HEPDART 2015 FINAL (Abstract 114)
11.15.2015 AASLD 2015 San Francisco Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in chronic HBV / HDV co-infection in Caucasian patients. Replicor REP 301 AASLD 2015 (Abstract 31)
10.7.2015 Int. Mol. Biol. HBV 2015 Bad Nauheim Antiviral effects of nucleic acid polymers on Hepatitis B virus infection in vitro (P-217) Replicor NAPs in vitro (HBV) HBV 2015 (P-217)
10.7.2015 Int. Mol. Biol. HBV 2015 Bad Nauheim Immunostimulatory properties of nucleic acid polymers (P-221) Replicor NAPs Immunostimulation HBV 2015 (P-221)
10.7.2015 Int. Mol. Biol. HBV 2015 Bad Nauheim Benefit of interferon-free, nucleic acid polymer-based combination therapy for chronic Hepatitis B (P-238) Replicor NAPs + NUCs in vivo HBV 2015 (P-238)
10.7.2015
Int. Mol. Biol. HBV 2015
Bad Nauheim Modifications of nucleic acid polymers decrease liver accumulation without affecting antiviral activity (P-239) Replicor Diff NAPs in vivo HBV 2015 (P-239)
10.7.2015 Int. Mol. Biol. HBV 2015 Bad Nauheim Activity of various nucleic acid polymers in blocking hepatitis delta virus entry in vitro (P-242) Replicor NAPs in vitro (HDV) HBV 2015 (P-242)
 6.25.2015 ISVHLD 2015 Berlin REP 2139 monotherapy and combination therapy with pegylated interferon:
Safety and potent reduction of HBsAg and HDV RNA in Caucasian Patients with chronic HBV / HDV co-infection (O-09)

ISVHLD 2015

Presentation

 4.25.2015 EASL ILC 2015 Vienna Significant reduction of HBsAg and HDV RNA by REP 2139-Ca in Caucasian patients with HBV / HDV co-infection (LO2) EASL 2015 Presentation
4.25.2015 EASL ILC 2015 Vienna HBV RNA analysis in Asian patients treated with REP 2139-Ca (O114) EASL 2015 Presentation
4.25.2015 EASL ILC 2015 Vienna Serum cytokine response in Asian HBV infected patients treated with REP 2139-Ca (P0659) EASL 2015 Poster
4.25.2015 EASL ILC 2015 Vienna Pre-clinical assessment of various NAPs in HBV infection (P0542) EASL 2015 Poster
4.25.2015 EASL ILC 2015 Vienna Activity of NAPs against HDV infection in vitro (LP26) EASL 2015 Poster
4.23.2015 EASL ILC 2015 Vienna Activity of NAPs against HBV infection in vitro (P0556) EASL 2015 Poster
4.10.2015 Lancet Hepatitis Summit 2015 Shanghai REP 2055 / REP 2139-Ca Asian Clinical data update Lancet Poster
10.12.2014 OTS 2014 San Diego REP 2055 / REP 2139-Ca Asian Clinical data update OTS Presentation
5.12.2013 TIDES 2013 Boston REP 2055 / REP 2139-Ca Efficacy and Safety TIDES Presentation
4.26.2013 EASL 2013 Amsterdam REP 2139-Ca Asian Clinical data EASL Poster